We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Dr. R. N. Lahoti Institute of Pharmaceutical Education and Research Centre Jalna Road, Sultanpur, Bhuladan
Cancer continues to be among the top causes of death globally, making new treatment strategies essential. Targeted drug delivery systems have surfaced as a promising approach to improve the effectiveness of cancer therapy while reducing adverse effects. These systems can enhance the drugs are concentrated in tumor tissues while exposure to healthy cells is reduced. The principles are underscored in this review, Benefits and difficulties of targeted drug delivery in cancer treatment, emphasizing approaches based on nanotechnology methods. Different kinds of nanocarriers, such as nanoparticles, dendrimers, liposomes and micelles, have demonstrated promise for the targeted delivery of drugs to cancer cells. Both active and passive targeting strategies have been investigated, with active targeting involving the use of ligands to attach to receptors that are overexpressed on cancer cells. Even with the potential of targeted drug delivery, additional research is necessary to address challenges like the swift elimination of nanocarriers from the organism and possible toxic properties. Nonetheless, the targeted delivery of drugs offers significant promise for enhancing cancer results of treatment and minimizing adverse effects.
In the majority of areas worldwide, cancer remains one of the leading causes of death. The disease’s early prognosis due to routine screening and a has enabled the development of many new treatment options. More profound understanding of the mechanism behind tumor progression. Following the surgical intervention of most solid tumors eliminated, the cancer cells that persist are addressed with various methods, including immunotherapy and chemotherapy, radiotherapy and additional [1]. Next to heart disease, cancer ranks among the leading causes of death and constitutes a major global health concern. The estimates indicated that in 2016, the number of new cases would exceed 1.6 million and over 500,000 deaths linked to cancer would occur in the US. Mortality rates associated with cancers of the liver, pancreas, and uterus are steadily increasing despite progress in treatment methods, even with enhanced diagnostic, preventive and therapeutic these measures have certainly contributed to a reduction in incidence rates for certain cancers, including prostate and colon cancer [2].Targeted drug delivery refers to the method of administering medication to a patient that increases the concentration of the drug in certain areas of the body relative others. Targeted drug delivery aims to enhance the drug concentration in targeted tissues while reducing its relative concentration in other tissues. This one mitigates negative effects and enhances the efficacy of the product. This mitigates adverse effects while enhancing the product’s efficacy [3]. The recognition is growing that cancer is a heterogeneous disease requiring personalized treatment strategies tailored to the genetic makeup, tumor characteristics, and clinical profiles of individual patients. The possibility that standardized treatment protocols emphasizes the need for personalized medical techniques might not meet each patient’s specific requirements effectively [4]. Drug design and development leverages a variety of nanotechnologies to tackle the basic shortcomings of cancer treatments, leading to medications that are safer and more effective [5]. Cancer is among the hardest diseases to treat, and despite the most advanced modern medical therapies, most cancer patients still succumb to the disease. While surgery can remove cancer focuses, it cannot eradicate micro-focuses or liberated cancer cells, which are often responsible for recurrences. The anticancer treatment chemotherapy is the primary supplementary treatment, yet it often fails because of its severe side effects that patients find intolerable. Over the past several decades, there have been impressive advancements in the field of cancer biology. Nonetheless, in spite of extraordinary advancements in the fundamental biology of cancer, these discoveries have not resulted in corresponding developments in clinical settings [6]. Cancer is among the hardest diseases to treat and despite the most sophisticated contemporary medical therapies, most cancer patients succumb. Although surgery can remove cancer focuses, it cannot eliminate micro-focuses or free cancer cells, which are often responsible for relapses. The anticancer treatment chemotherapy is the primary supplementary treatment, yet it often fails because of its severe side effects that patients find intolerable. In the past several decades, research in cancer biology has progressed at an extraordinary pace [7]. Nanotechnology offers significant promise for surmounting these barriers by enabling the encapsulation of large amounts of therapeutic drugs within nanoparticles. This enhances both the pharmacokinetic profile and therapeutic efficacy of medications by extending their half-life and reducing adverse effects [8]. In the last few decades, researchers have highlighted nanotechnology, a remarkable technological trend encompassing the rapid growth of electronics for application in environmental oversight, communication and medical services (referred to as nanomedicine). The scientific community bottlenecks impacting the lifespan of living beings, especially humans, are widely discussed in current investigation. Most of these bottlenecks result from diseases that have few or no alternative treatment options and recovery [9]. For most cancers, symptoms appear only after a considerable number of healthy cells in the body have been converted into malignant cells by these invisible factors. These “rebellion cells” proliferate throughout the lymphatic system, leading to the formation of additional tumors in adjacent tissues and organs [10] Cancers are categorized into various types, such as carcinoma, sarcoma, lymphoma, leukemia, germ cell tumor and blastoma, based on the presumed origin of the tumor cells. Of these, carcinoma refers to cancer that starts in the epithelial cells and encompasses nearly all cancers affecting the breast, prostate, lung, pancreas and colon. Cancer is a category of ailments triggered by uncontrolled cellular proliferation and these atypical cells can disseminate or encroach upon other regions of the body [11]. Neoplasms developing in the lips, hard palate, buccal mucosa, anterior two-thirds of the tongue, sublingual area, upper and the lower alveolar ridges, retro molar trigons and floor of the mouth are classified as oral cancer [12]. Although there are current hindrances, TMAs are rightly undergoing further development and drawing increased commercial interest, which demonstrates the dedication and skill of many scientists and engineers in laboratories worldwide [13]. Furthermore, it is anticipated that the count of deaths linked to cancer will increase, with around 12 million fatalities projected for 2030. It is thus essential to create effective methods for monitoring, diagnosing and treating cancer, although this remains a challenge. At the moment cancer therapies available include chemotherapy, radiation therapy, surgery and others [14]. To tackle the disadvantages of the oral route, though, the parenteral route is the most commonly used natural alternative. Traditionally, medications are administered parenterally using a syringe and a hypodermic needle. Although being the natural and costly) alternative, the parenteral method carried several risks for patients, such as intense pain, The formation of a thrombus at the site of administration and hypersensitivity [15]. A system for the targeted delivery of medication functions by providing a defined amount of a therapeutic agent to a designated diseased site in the body for a prolonged duration of time this maintains stable plasma and tissue drug levels in the body, preventing harm to healthy gewebe [16]. Advancements in nanotechnology have led to the development of novel nanomaterials with physico-chemical properties (such as a greater surface-to-volume ratio) that make them promising candidates for use in biomedical science. “Nanomedicine” represents a novel area of science and engineering that could greatly change both personal and health care that focuses on populations via its use in illness screening, diagnosis and treatment [17]. Konzeptionieren the most direct and controllable approach among all of them is to use nanoparticles whose sizes can be adjusted. Many studies have shown a robust connection between the dimensions of nanodrugs and their anticancer efficacy [18]. Nanocarriers have been extensively studied in recent decades due to their promising potential in drug delivery. Due to their elevated surface area-to-volume ratio, nanocarriers have the ability to alter the essential properties and bioactivity of drugs. Among the traits that nanocarriers can confer to drug delivery systems possess improved pharmacokinetics andbiodistribution, decreased toxicities, enhanced solubility and stability, controlled discharge and targeted delivery of therapeutic agents [19].
2. Necessity for targeted medication delivery
It is necessary to implement targeting in order to surmount the limitations and intrinsic disadvantages of conventional DDSs. Oral administration is not an option for medications produced from proteins or topical lotions and ointments can only have local effects, peptides and parenteral delivery is highly invasive. In addition, unless the treatment is given at a dosage and rate that achieves the highest therapeutic effects with the least side effects, the effectiveness of drug–target interactions is put at risk. Moreover, TDD offers the potential advantages of simpler drug administration procedures, reduced drug quantity and therapeutic costs and a significant increase in drug concentration in target compartments without affecting nontarget compartments. As a rule, drug targeting leads to enhanced efficacy, pharmacokinetics that are modulated, biodistribution that is controlled, increased localization specificity and reduced toxicity diminished dosage and enhanced patient adherence [20].
3. Principles of targeted drug delivery
Targeted drug delivery aims to reduce exposure to healthy tissues while accurately delivering therapeutic medicines to the site of action, such as diseased tissues or cells. Targeted drug delivery systems employ various mechanisms to enhance the precision, correctness and effectiveness of drug delivery, as opposed to systemic administration, which delivers drugs to various parts of the body via blood circulation. Several factors form the basis of targeted drug delivery basic concepts [4].
4. Benefits of drug targeting
• The procedure for administering the drug becomes easier.
• Aiming for a specific location diminishes the drug’s toxicity.
• A minute dose can elicit the desired pharmacological response.
• Avoid the first-pass effect.
Figure 1 The need for targeted drug delivery [19]
5. Drawbacks of drug targeting [21]
• Redistributing and disseminating approved medications.
• Experts must oversee and regulate the provision to the site of application.
• First metabolic processing, dietary interactions, degradation of microflora in the digestive tract, and so on.
• Low bioavailability rate.
6. Cancer therapy with targeted delivery
A key difficulty in delivering medication via nanocrystals is reaching the target site while avoiding an increase in nonspecific toxicity. Considering that the body is made up of successive barriers, it is easy to comprehend how medication suboptimal accumulation at the target site may lead to unwanted bio-distribution to healthy tissues [22]. Nowadays, a variety of targeted therapies are used to treat cancer. It is possible to better comprehend the functioning of these medications by studying examples. Various categories of drugs are utilized in targeted therapy [23].
6.1. Delivery without action
It has been shown that non-functionalized nanoparticles are quickly eliminated from the bloodstream as they are absorbed by the liver, lungs, spleen and kidneys. The intercellular connections of the vascular endothelium are closely congested, which prevents nanoparticles from accessing healthy tissues. As tumor tissues develop, an inflammatory response takes place, marked by heightened vascular permeability. This expansion of the endothelium permits nanoparticles to infiltrate and get through cancerous tissues [22].
6.2. Delivery with proactive approach
Due to a decrease in systemic toxicity and therapeutic efficacy, they could not replace traditional chemotherapy medications. An active targeting technique can be employed to tackle this limitation, which will elevate the degree of nanocarrier concentration and bioavailability at tumor sites. In order to facilitate the targeted transport of the to direct the nanoparticle to specific cells or tissues, various targeting ligands, comprising both antibodies and non-antibodies, are employed. These consist of proteins such as transferrin, peptides like RGD, vitamins such as folic acid and aptamers [24]
Figure 2 Schematic representing different drug targeting approaches to tumor [1].
7. Approaches for drug targeting in the treatment of cancer
The main issue with combination chemotherapy is ensuring that the anticancer drugs delivered together reach healthy cells. Usually, the medication provided alongside treatment interrupts metabolic processes, produces negative effects and damages both malignant and well-functioning cells. The delivery of anticancer drugs to healthy tissues reduced their concentration and efficacy at the target location. To circumvent this limitation, targeted strategies must be improved. Nanocarriers have demonstrated efficacy in targeting drugs to cancer cells when used alongside chemotherapy. With reduced cytotoxicity and extended blood circulation times in a targeted manner. Active and passive targeted treatment the two commonly employed targeting strategies are delivery. Whereas passive targeting exploits aberrant active targeting depends on ligands linked to nanocarriers that can connect fenestrations on the surface of tumor cells with the receptors that are expressed to a greater than normal degree on the surface of the targeted cells [25].
Figure 3 Mechanism of passive targeting and active targeting [20]
8. Key characteristics of targeted drug delivery systems [26]
For a medicine to have the expected effect, it must physically touch its target and maintain contact with the targeted area for an adequate duration. Not every drug can be delivered through drug delivery systems.
9. Drug delivery using magnets
A drug carrier that possesses magnetic properties is directed to a designated area within the body through the application of an external magnetic field. This is the concept behind magnetic drug delivery. Especially in the realm of biomedicine, magnetite and maghemite are the most commonly used magnetic minerals among the various types of MNPs.Capability of magnetic hyperthermia in systems that deliver drugs magnetically. A method of treating cancer known as Hyperthermia employs high temperatures to eliminate tumor cells. The term “hyperthermia” is derived from greek etymology. Which consists of the terms “hyper,” meaning “rise” in a literal sense and “thermal,” which physically translates to “heat.” Hyperthermia is a process that entails generating heat at the tumor-cell level and elevating temperature to a target range. frequently within the range of 41°C to 46°C for a span of 20 to 60 minutes in order to eliminate tumor cells.
Figure 4 Nanostructured NPs with their average preparatory-method-dependent diameter [10].
10.1. Nanoparticles
Nanoparticles, which are solid supramolecular structures, are ultradispersed and vary in size from 10 to 1,000 μm. 95– 97 Drugs can be incorporated into a matrix of nanoparticles, serving as a reservoir, through methods such as dissolution, entrapment, encapsulation or bonding. For particulate systems and is essential for the administration of therapeutic drugs, particularly in oncology [27].
10.2 Dendrimers
Dendrimers are characterized as unique nanostructures measuring between 1 and 10 nm. Composed of branching chains that encircle a central core, dendrimers feature surface functional groups on their exterior. The area between the branched chains in the central allows for the transport of medications or chemicals to the target site essence. Various types of dendrimers can be produced based on the underlying structure the most frequently utilized variety of dendrimers consist of clusters of poly (amidoamine) (PAMAM) units [28].
10.3. Liposomes
Liposomes were first characterized in 1968. These are minute synthetic spherical vesicles made from cholesterol and non-toxic, naturally occurring phospholipids. Liposomes are appealing as drug delivery vehicles due to their size, Ease of production, hydrophobic nature and compatibility with biological systems. Advancements in liposomal vesicles have resulted in customized Medication delivery (targeting specific diseases) and regulated medication release. As a result of chemotherapy, radiation therapy and surgical resection are the primary cancer treatments, this feature is essentially advantageous for treating cancer [26]. Liposomes are lipid bilayers that have been artificially formed into vesicular structures. Whilst lipid-soluble and amphiphilic drugs embed themselves in the phospholipid bilayer, while water-soluble drugs are located in aqueous compartments. Liposomes are becoming popular for various applications, including the delivery of medicine in nutrition. [29].
10.4. Micelles
Micelles consist of amphiphilic particles dispersed in a liquid. A lipophilic emulsion that is not sufficiently water-soluble for convenient administration can be solubilized in the core area of the micelle. Block-copolymer pluronic The most studied micellar nanocarriers are based on micelles. Their effect on enhanced drug transport across the blood-brain barrier was demonstrated through both in vitro and in vivo studies. The amphiphilic components in micelles and the bulk products are continuously swapping positions. On the other hand, polymeric micelles, also known as polymersomes, are polymer shells assembled from block copolymer amphiphiles resembling polyethylene glycol-polylactic acid and made with a tone assembly (cut-PLA) sowie cut-polycaprolactone (cut-PCL) [30].
10.5. Cyclodextrins
When starch is enzymatically degraded, a kind of cyclic oligosaccharides called cyclodextrins (CD) is formed. CD can aggregate hydrophobic guest molecules, including those with anticancer properties, through host-gust inclusion interactions. The drugs docetaxel, cisplatin, methotrexate, and paclitaxel [31].
10.6. Hydrogel
Hydrogels have been used for over 50 years in various biological fields, including ophthalmology (for contact lenses) and multiple therapeutic contexts to address conditions such as diabetes mellitus, osteoporosis, asthma and heart disease and neoplasms [32].
10.7. Liquid crystals
Materials that are in a differential state and show traits of both solids and liquids are referred to as LCs. This stage is called the mesophase, as the prefix “meso-“denotes “intermediate.” There are two categories of LCs: lyotropics, which stem from their connection with amphipathic substances, solvents, and thermotropics, which are organized by thermic condition. The majority of mesophase lyotropics are cubic, hexagonal or lamellar [27].
11. Cancer treatment using nanotechnology
Detecting cancer at the very beginning of the carcinogenic process is essential for effective cancer treatment. Research findings in the field of nanotechnology are encouraging the scientific community to create innovative, non-invasive tools. For these applications at the nanoscale.
11.1. Nanoparticles with magnetic properties
Magnetic nanoparticles are iron oxide particles that have sugar molecules wrapped around them. Consequently, The immune system cannot identify these. These particles are capable when subjected to an external magnetic field to raise the temperature and eliminate tumor cells, while sparing healthy tissues. Magnetic nanoparticles that are biodegradable have been developed by a group of researchers using nanosized magnetites and organic polymers.
11.2. Colloidal gold nanoparticles
Currently, colloid gold nanoparticles are being developed as a potential means of delivering medication for cancer treatment. A variety of treatment theories exist, and thorough investigations are underway to scrutinize the impacts of these methods.
11.3. Micellen aus Polymeren
Due to their ability to release hydrophobic anticancer medicines in a regulated manner and selectively target specific cells, polymeric micelles are an groundbreaking medication delivery technology. Conjugation of poly(ethylene glycol)-poly(α,β-aspartic acid) block copolymer doxorubicin has been demonstrated to effectively transport cytotoxic drugs to cancer cells using polymeric micelles[33].
12. Environmental carcinogenic risk factors
12.1. Physical elements
12.1.1. Strahlung mit ionisierender Wicking
A frequently cited carcinogen, ionising radiation can lead to tumours in any organ where the cancer arises independently. As a result of the observations of children who had undergone prenatal RTG and children who had after surviving the bombings of hiroshima and nagasaki, the initial research on the dangers of ionizing radiation was carried out in the 50s and 60s of the 20th century. Leukaemia and thyroid cancer are becoming more frequent.
12.1.2. Ultraviolet radiation
The skin is most commonly affected by UV light, which has the most harmful effect on it. In besides late-phase markers of sped-up skin ageing and post-solar carcinogenesis, lengthy.
12.2. Chemical influences
12.2.1. Tobacco smoking
Tobacco use is the primary preventable risk factor for cancer deaths, accounting for approximately 6 million fatalities globally each year. As stated by the WHO FCTC, all tobacco products, whether composed entirely or partially of tobacco leaves intended for chewing, sniffing and smoking are sources of numerous carcinogens and other harmful substances.
12.2.2. Ethanol
Studies in epidemiology show that drinking alcohol is associated with a heightened cancer risk. Drinking raises the likelihood of cancer in the mouth, throat, larynx, esophagus, liver and breast. Biological components
12.3.1. Nutrition
Malignant tumor development is largely attributable to poor dietary habits. Due to the advancement of civilizations, numerous hazardous materials with carcinogenic effects exist in the environment and in food and the nearby areas.
12.3.2. Mutagenic and carcinogenic substances in food
Depending on environmental factors, mutagenic and carcinogenic substances can be found in various food products. These can either be natural substances or arise from the storage and processing of food. The majority of them are categorized as genotoxins, namely active forms of mutagen that covalently attach to the DNA molecule and alter the nitrogen bases, which results in the synthesis of a protein containing the substituted sequence.
12.3.3. Infections
Infectious agents that play a significant role in the etiology of various diseases are garnering increasing attention regarding their involvement in cancer development [34].
CONCLUSION
By delivering therapeutic agents directly to the site of action, targeted drug delivery systems enhance efficacy and minimize side effects, making them a promising approach for effective cancer treatment. Based on nanotechnology methods such as nanoparticles, dendrimers, liposomes and micelles have demonstrated significant promise in providing drugs directed specifically at cancer cells. Both active and passive targeting strategies have been examined, with active aiming to use ligands for attachment to receptors that are present in excessive quantities on tumor cells. Although difficulties like swift elimination of the body and potential toxicity of nanocarriers need to be addressed, targeted drug delivery holds great promise for enhancing the results of cancer therapies while minimizing adverse effects.To refine targeted drug delivery systems and implement them in clinical practice, additional research is necessary. As nanotechnology and targeted drug delivery continue to advance, these systems are likely to become increasingly important in cancer treatment as well as other illnesses.
REFERENCES
Gayatri Khanderao*, Arun Mante, Samadhan Magar, Nitin Lodhe, Anata Gite, Shivaji Mohrut, Nilesh Sawadadkar, Nandu Kayande, A Review on Targeted Drug Delivery in Cancer Therapy: Advances, Challenges, and Future Perspectives, Int. J. Med. Pharm. Sci., 2026, 2 (5), 267-275. https://doi.org/10.5281/zenodo.20057718
10.5281/zenodo.20057718